Dithranol (Anthralin) in Vitiligo
Dithranol is not recommended for vitiligo treatment and has no established role in standard vitiligo management. The available evidence does not support its use for repigmentation in vitiligo, and it may cause increased irritation in depigmented skin.
Why Dithranol Should Not Be Used
Lack of Evidence for Efficacy
- None of the major vitiligo guidelines 1, 2, 3, 4 recommend dithranol/anthralin for vitiligo treatment
- The drug is FDA-approved only for psoriasis, not vitiligo 5
- No clinical trials demonstrate repigmentation efficacy in vitiligo patients
Safety Concerns in Vitiliginous Skin
Research shows dithranol causes increased inflammatory response in vitiliginous skin compared to normally pigmented skin:
- Studies demonstrate stronger erythematous reactions in depigmented areas 6
- Increased granulocyte and monocyte infiltration occurs in vitiliginous skin exposed to anthralin 6
- The protective melanin scavenging effect is absent in depigmented skin, potentially increasing oxidative damage 6
Practical Drawbacks
- Causes permanent staining of skin, hair, and fabrics 5
- Produces transient primary irritation 5
- Requires careful application to avoid contact with eyes and mucous membranes 5
Recommended Alternatives for Limited, Stable Vitiligo
First-line therapy:
- Topical corticosteroids for body sites 2, 7, 3
- Topical calcineurin inhibitors (tacrolimus, pimecrolimus) for face, neck, genitals, and intertriginous areas 2, 7, 3
- Topical ruxolitinib cream (JAK inhibitor) - newer FDA-approved option 2, 3
Phototherapy options:
- Narrowband UVB (3 times weekly) - superior to PUVA 1, 3
- Excimer laser/lamp for localized lesions 1, 3
- Can be combined with topical therapies 7, 3
For refractory stable disease:
Critical Pitfall to Avoid
Do not confuse dithranol's role in psoriasis with any indication for vitiligo - these are entirely different disease mechanisms. Dithranol works through antiproliferative effects appropriate for psoriasis 5, 8, but vitiligo requires melanocyte stimulation and immune modulation, not antiproliferation.